Jianming Xu

28PUBLICATIONS
65CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityMolecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Apr 29, 2026
Comparative effectiveness of first-line taxane-platinum versus fluorouracil-platinum chemotherapy in advanced esophageal squamous cell carcinoma: a propensity score-matched real-world study.

|Mar 06, 2026
Expansion of IL-2-independent tumor-infiltrating lymphocytes through a feeder-free process: a preclinical study for solid tumors.

Ying Zhang, Sicheng Du, Rongrui Liu

|Mar 02, 2026
First-line immunotherapy for advanced HER2-negative gastric cancer: differences between Asian and non-Asian patients.

Chuanhua Zhao, Sisi Ye, Meng Chen

|Nov 22, 2025
Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01).

Chuanhua Zhao, Jun Zhao, Yigui Chen

|Nov 10, 2025
Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity.

Sicheng Du, Ying Zhang, Ruidong Hao

|Sep 30, 2025
Current progress in neoantigen-based dendritic cell vaccines for solid tumors.

Yuting Li, Abudukadierjiang Abudureheman, Jianming Xu

Pageof 5

Frequent Collaborators

3 joint publications

Ying Cheng

2 joint publications

Eric Van Cutsem

2 joint publications

Lucjan Wyrwicz

2 joint publications

Sisi Ye